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Introduction
Post-transplant lymphoproliferative disorder (PTLD) is a seri-
ous complication after solid organ (SOT) and hematopoietic
stem cell transplantation (HSCT). PTLD encompasses a het-
erogeneous morphologic spectrum, ranging from EBV driven
polyclonal proliferations to aggressive monomorphic large B
cell lymphomas. According to theWorld Health Organization,
PTLD can be classified into 4 main groups: non-destructive
lesions, polymorphic PTLD, monomorphic PTLD, and clas-
sical Hodgkin lymphoma PTLD [1].
PTLD has a variable clinical presentation that may include
B-symptoms, lymphadenopathy, organ/allograft dysfunction,
or a combination of non-specific symptoms. It is characterized
by a bimodal presentation curve, with a peak incidence within
1 year after transplantation and a second peak after 4–5 years
[2, 3]. However, the diagnosis of PTLD can be made at any
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Abstract
Purpose Post-transplant lymphoproliferative disorder (PTLD) is a serious complication after solid organ and hematopoietic stem
cell transplantation, requiring a timely and accurate diagnosis. In this study, we evaluated the diagnostic performance of FDG-
PET/CT in patients with suspected PTLD and examined if lactate dehydrogenase (LDH) levels, Epstein-Barr virus (EBV) load,
or timing of FDG-PET/CT relate to detection performance of FDG-PET/CT.
Methods This retrospective study included 91 consecutive patients with clinical suspicion of PTLD and a total of 97 FDG-PET/CT
scanswithin an 8-year period. Pathology reports and a 2-year follow-upwere used as the reference standard. Diagnostic performance of
FDG-PET/CT for detection of PTLD aswell as logistic regression analysis for factors expected to affect diagnostic yieldwere assessed.
Results The diagnosis of PTLD was established in 34 patients (35%). Fifty-seven FDG-PET/CTscans (59%) were true negative,
29 (30%) were true positive, 6 (6%) false positive, and 5 (5%) false negative. Sensitivity of FDG-PET/CT for the detection of
PTLD was 85%, specificity 90%, positive predictive value 83%, and negative predictive value 92%, with good inter-observer
variability (k = 0.78). Of the parameters hypothesized to be associated with a true positive FDG-PET/CT result for the diagnosis
of PTLD, only LDH was statistically significant (OR 1.03, p = 0.04).
Conclusion FDG-PET/CT has a good diagnostic performance in patients suspected of PTLD, with a good inter-observer agree-
ment. Only LDH levels seemed to influence the detection performance of FDG-PET/CT. EBV-DNA load and timing of FDG-
PET/CT after transplantation did not affect FDG-PET/CT diagnostic yield.
Keywords Post-transplant lymphoproliferativedisorder . 18F-Fluoro-D-deoxyglucosepositronemission tomography .FDG-PET/
CT . Diagnosis
time after transplantation and diagnostic work-up is usually
initiated by the presence of B-symptoms and biochemical
anomalies such as an increase in lactate dehydrogenase
(LDH) and detectable Epstein-Barr virus (EBV) DNA. In
PTLD, elevated LDH has been associated with a lack of re-
sponse to initial therapy and worse prognosis [4–6]. EBV is
recognized to play a crucial role in the immunopathogenesis
of PTLD and EBV-DNA load monitoring is routinely per-
formed for early detection of PTLD [7]. However, LDH and
EBV-DNA load are non-specific for the detection of PTLD
and particularly EBV-DNA load is not useful in EBV-negative
PTLD which may compromise up to 50% of PTLD cases
[8–10]. During diagnostic work-up, 18F-fluoro-2-deoxy-D-
glucose (FDG) positron emission tomography (PET)/comput-
ed tomography (CT) may also be performed, allowing for
whole-body visualization of metabolic active lesions and di-
rect biopsy localization.
Materials and methods
Study design and patients
This retrospective study included all consecutive patients be-
tween January 2010 and January 2019 for whom an FDG-
PET/CT scan was requested. Indications for FDG-PET/CT
requests are described in Table 1. The first FDG-PET/CT or
in some patients the second scan after a 2-year negative
follow-up period was included in the analysis (see
“Reference standard”). Only patients 19 years and older were
included. Patients with central nervous system involvement,
complete tumor resection prior to FDG-PET/CT evaluation,
and those without a biopsy or 2-year follow-up were
excluded.
Patient record review
Relevant clinical and biochemical data were collected from
the electronic patient files at the University Medical Center
Groningen. These included age, gender, organ transplanted,
time between transplantation and FDG-PET/CT, LDH levels,
EBV-DNA load, and PTLD morphology and histology.
FDG-PET/CT acquisition and interpretation
All FDG-PET/CT scans were performed on a Siemens
Biograph 40 or 64 slice mCT (Siemens Healthineers,
Erlangen, Germany) according to the European Association
of Nuclear Medicine (EANM) procedure guidelines for tumor
imaging [13]. Scans were performed after a minimum fasting
time of 6 h. Images from the mid-thigh to skull base were
acquired 60 min after intravenous administration of 3 MBq/
kg FDG. Integrated FDG-PET/CT images were corrected for
scatter and attenuation based on CT information. Scans were
retrospectively reviewed by 3 readers (2 experienced nuclear
medicine physicians (AG and WN) and 1 research fellow
(FMJ) using syngo.via software (Siemens Healthineers,
Erlangen, Germany). Readers reviewed the scans indepen-
dently from each other and were blinded for other clinical/
imaging findings and pathology results. Scans were consid-
ered positive for PTLD when FDG-avid lesions were present
that could not be related to other pathology than PTLD. Scans
were considered negative when no FDG-avid lesions suspi-
cious for PTLD were found. Scans were considered equivocal
when FDG-avid lesions were present, but this uptake could be
due to either PTLD or due to other diseases/malignancy. In
these cases, a differential diagnosis was noted. Discordant
results between readers were re-evaluated in a consensus
Table 1 Indications for FDG-
PET/CT request* N (%)
Blood panel disturbances
(e.g., complete blood count and biochemistry)
20 (20.6)
High EBV-DNA load 44 (45.3)
Physical symptoms
(e.g., B-symptoms, enlarged lymph nodes, other non-specific symptoms)
37 (38.1)
Anomalies previous examination
(e.g., colonoscopy, other non FDG-PET/CT imaging)
38 (39.2)
*Multiple indications possible for a single scan
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Although FDG-PET/CT is an established imaging modal-
ity in the detection of other FDG-avid lymphomas, with a
reported median sensitivity of 90% and specificity of 91%,
its diagnostic performance has not been extensively evaluated
in PTLD [11, 12]. FDG-PET/CT may become an essential
part of the diagnostic work-up in PTLD patients if proven to
be of additional value for the detection of this disorder.
However, biomarkers such as LDH, EBV-DNA load, and
timing of FDG-PET/CT after transplantation may also influ-
ence its diagnostic yield. The purpose of this study was to
evaluate the diagnostic performance of FDG-PET/CT in pa-
tients with suspected PTLD and to examine if LDH levels,
EBV-DNA load, and timing after transplantation influence
the detection performance of FDG-PET/CT.
meeting and conclusively classified as positive or negative for
PTLD.
Reference standard
Pathology reports were used as a reference standard for
PTLD diagnosis. Two experienced hematopathologists
(SR, AD) were consulted for morphology clarification
when necessary. In case of a PTLD-negative biopsy or
lack of tissue for pathological examination, a 2-year
follow-up period without pre-emptive PTLD therapy
was accepted as the reference standard. Absence of lym-
phoma during this period has been shown to be an
accurate marker for lack of disease in other lymphomas
[14, 15]. True positive cases were defined as a PTLD-
positive FDG-PET/CT and a PTLD-positive pathology
result within 2 years after FDG-PET/CT. True negative
cases were defined as a PTLD-negative FDG-PET/CT
and no signs of PTLD within 2-year follow-up. False
positive cases were defined as a PTLD-positive FDG-
PET/CT and no signs of PTLD within a 2-year follow-
up. False negative results were defined as a PTLD-
negative FDG-PET/CT and pathology proven PTLD
within a 2-year follow-up period.
Statistical analysis
Baseline patient characteristics were summarized using
medians with interquartile range (IQR) for non-
normally distributed variables. Sensitivity, specificity,
positive predictive value (PPV), and negative predictive
value (NPV) of FDG-PET/CT for the detection of
PTLD were calculated with a 95% confidence interval
(CI). Logistic regression model analysis was carried out
using mean serum LDH levels, mean EBV-DNA load
(mean over a 31-day period before FDG-PET/CT), and
time between transplantation and FDG-PET/CT with
FDG-PET/CT result as a dependent variable. FDG-
PET/CT results were dichotomized as true positive or
not true positive (i.e., false positive, true negative, and
false negative combined). The corresponding odds ratio
(OR) and 95% CI were calculated. Statistical signifi-
cance was set at p value ≤ 0.05. Inter-observer variabil-
ity between the 3 observers was calculated using Fleiss
kappa. The kappa value was interpreted according to the
method of Landis and Koch: poor (0 to 0.20), fair (0.21
to 0.40), moderate (0.41 to 0.60), good (0.61 to 0.80),
and perfect agreement (0.81 to 1) [16]. All statistical
analyses were performed using SPSS, version 23.0
(IBM Corporation, Armonk, NY, USA).
Results
Patients
One-hundred-twelve potentially eligible patients were identi-
fied. Eleven patients were excluded due to central nervous
system involvement, 6 due to complete tumor resection prior
to FDG-PET/CT evaluation, and 4 due to lack of a reference
standard. In total, 91 patients and 97 FDG-PET/CTscans were
included in this study (Table 2). In 6 patients, 2 FDG-PET/CT
scans were included because of PTLD suspicion on two dif-
ferent occasions with a time interval of more than 2 years.
There were 50 males (55%) and 41 females (45%) with a
median age of 54 years. The most frequently transplanted
organ was the lung (n = 40, 44%) followed by the kidney
(n = 31, 34.1%), liver (n = 11, 12.1%), HSCT (n = 4, 4.4%),
multi-organ (n = 4, 4.4%), and the heart (n = 1, 1.1%).
According to the reference standard, 34 patients (35%) were
diagnosed with PTLD. There were 21 EBV-positive PTLDs
(62%) and 13 EBV-negative PTLDs (38%). The median time
Table 2 Patient characteristics (n = 91)



























IQR interquartile range, HSCT hematopoietic stem cell transplantation
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between transplantation and FDG-PET/CTwas 5 years (IQR;
9).
Diagnostic performance of FDG-PET/CT
After a consensus meeting, the three readers assessed 35 scans
to be positive for PTLD and 62 scans negative. Pathology
confirmation was the reference standard in 64 scans (66%)
and 2-year follow-up in 33 (34%). According to the reference
standard, 57 scans (59%) were true negative, 29 (30%) were
true positive, while 6 (6%) false positive, and 5 (5%) false
negative results were observed (Table 3, Fig. 1). On a
patient-based analysis, sensitivity of FDG-PET/CT for the de-
tection of PTLD was 85%, specificity 90%, PPV 83%, and
NPV 92% (Table 4).
False positive and false negative scans
Determinants of detection performance
of FDG-PET/CT
According to univariate logistic regression, the only statisti-
cally significant parameter associated with a true positive
FDG-PET/CT scan was serum LDH level with an OR of
1.03 (p = 0.04, 95% CI;1.001–1.06). Hence, for each 10 unit
increase in LDH, the odds of having a true positive FDG-PET/
CT scan were 3% higher. The remaining parameters, EBV-
DNA load (OR; 1.0, p = 0.59, 95% CI;1.00–1.00), and time
between transplant and FDG-PET/CT (OR; 1.05, p = 0.23,
95% CI;0.97–1.12) were not statistically significant in the
univariate logistic regression analysis. For this reason, a mul-
tivariate logistic regression analysis was not performed
(Table 6). Sub-analysis of only EBV-positive PTLD patients
also revealed statistically insignificant results (OR; 1.0, p =
0.64, 95% CI;1.00–1.00).
Inter-observer variability
From a total of 97 FDG-PET/CT scans evaluated prior to
consensus, discordant results were reported in 14 scans. The
majority of discordant results were due to FDG uptake in the
lung parenchyma (n = 7). The differential diagnosis for these
lesions included PTLD, primary lung tumor or infection.
There were 5 cases of discordant results observed in the gas-
trointestinal tract and 1 discordant result for lesions in the
pelvic area, in which observers reported difficulty in
distinguishing between pathological and physiological up-
take. Finally, 1 discordant finding, located in the adenoids of
a young patient, was difficult to characterize as either patho-
logical or physiological/infectious. From the 14 discordant
FDG-PET/CT scans, 2 were false positive and 3 were false
negative. The inter-observer variability was found to be good
at k = 0.78 (95% CI; 0.68–0.88).
Discussion
Although metabolic imaging with FDG-PET/CT has an
established role in the diagnosis of non-Hodgkin and
Hodgkin lymphoma, few studies have been carried out to
assert its detection performance in PTLD [11, 17]. In our study
population, compromising of 97 FDG-PET/CT scans in 91
patients with suspected PTLD, we found a sensitivity of
85%, specificity of 90%, PPVof 83%, and NPVof 92% with
good inter-observer variability (k = 0.78). Of the determinants
hypothesized to influence detection performance of FDG-
PET/CT, only LDH levels were statistically significant with
an OR of 1.03 (p = 0.04, 95% CI;1.001–1.06).
Current guidelines from the British Committee for
Standards in Hematology, the British Transplantation
Society, and National Comprehensive Cancer Network





PET positive 29 (29.9) 6 (6.2)
PET negative 5 (5.1) 57 (58.8)
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In total, 6 scans were found to be false positive (Fig. 2). The
final diagnoses of these false positive scans were as follows: 1
case of condyloma acuminata in the recto-uterine pouch, 1
case of an adenomatoid tumor in the round ligament, 1 case
of small cell carcinoma in the transplanted lung, 1 case of
systemic Nocardia infection, 1 case of Aspergillus infection
in the lungs, and 1 case of spontaneous recovery of the
suspected lesions without medical intervention, considered
very unlikely to be PTLD. False positive results could be
divided into two main categories: (1) other malignancies also
showing high FDG uptake, making the differentiation be-
tween PTLD and other malignancy difficult and (2) infections,
also taking up FDG and leading to a differential diagnosis of
PTLD or infection. Five scans were concluded to be false
negative: 2 cases with focal uptake in the tonsils/adenoid,
interpreted as physiological uptake but confirmed to be non-
destructive PTLD, 1 case with focal uptake in the rectum,
interpreted as physiological uptake but confirmed to be poly-
morphic PTLD, 1 case with uptake in the lungs, interpreted as
a primary lung tumor or infection but confirmed to be classic
Hodgkin type PTLD, and 1 case considered to be a lung infil-
trate without FDG-uptake but confirmed to be monomorphic
PTLD (Table 5).
include no concrete recommendations on the use of FDG-
PET/CT for diagnosing PTLD [18, 19]. The good diagnostic
performance demonstrated in this study indicates that FDG-
PET/CT is a valuable imaging modality for detecting PTLD.
The good inter-observer variability also indicates that FDG-
PET/CT interpretation was minimally reader dependent be-
tween two nuclear physicians and a junior reader. We identi-
fied common limitations associated with FDG-PET/CT false
positive results such as inflammatory conditions and other
malignancies in addition to false negative results in non-
destructive and polymorphic PTLD, specific to this patient
population. Because non-destructive lesions are commonly
found in Waldeyer’s ring, such lesion location may be prone
to be interpreted as physiological uptake [20, 21].
Although the majority of studies published on the diagnos-
tic performance of FDG-PET/CT in PTLD are limited to case
series, studies by Panagiotidis et al. and Dierickx et al. also
reported good FDG-PET/CT diagnostic performance [22, 23].
Panagiotidis et al. included 40 patients with suspected PTLD
and compared FDG-PET/CT diagnostic performance with
CT. They concluded that FDG-PET/CT plays a significant
role in the diagnosis of PTLD with high detection accuracy
(sensitivity 88%, specificity 91%, PPV 88%, and NPV 91%)
[22]. Some limitations of the study by Panagiotidis et al. in-
cluded a smaller study population, half of that included in our
study, and FDG-PET/CT scans were evaluated by a nuclear
medicine physician and a radiologist without blinding for clin-
ical data. Dierickx et al. investigated FDG-PET/CT diagnostic
performance in 125 cases and reported high sensitivity of
FDG-PET/CT in detecting PTLD (sensitivity 90%, specificity
89%, PPV 85%, and NPV 93%) [23]. However, their study
was performed between 2003 and 2010 with 43% of the study
population scanned with a stand-alone PET system and no
information on the duration of follow-up in negative cases.
A recent systematic review on the clinical performance of
different imaging modalities in the diagnosis and treatment
response evaluation of PTLD patients reported FDG-PET(/
CT) to be the most frequently used imaging modality and a
promising tool in this setting [24]. In the same review, false
positive results were reported due to inflammatory conditions
while false negative results occurred in areas of high physio-
logical background activity and in non-destructive PTLD le-
sions. These results not only indicate the utility of FDG-PET/
CT in PTLD patients but also concur with some of the findings
in this study regarding potential causes for false positive and
false negative results.
From the parameters hypothesized to be associated with a
true positive FDG-PET/CT result for the diagnosis of PTLD,
only LDH had a statistically significant odds increase.
Uncontrolled proliferation of malignant cells with high cellu-
lar turnover is characterized by increased glycolysis and LDH
release. High energy metabolism may translate into higher
FDG uptake in tumor tissue and seemingly increase FDG-
PET/CT detection performance [25]. Nevertheless, the influ-
ence of LDH levels on the detection performance of FDG-
PET/CT should be confirmed in future research given the fact
that the lower boundary of the 95% CI of the OR was close to
1 in the present study. The role of EBV in the pathogenesis of
PTLD is well documented; however, EBV-DNA load was not
associated with true positive FDG-PET/CT results in our
study [26]. EBV monitoring is a common clinical practice
for early PTLD detection and various studies have advocated
Table 4 Detection performance of FDG-PET/CT in PTLD
Analysis Value % 95% CI
Sensitivity 85 68–94
Specificity 90 80–96
Positive predictive value 83 66–93
Negative predictive value 92 81–97
Accuracy 89 81–94
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Fig. 1 A 49-year-old male pre-
sented with low LDH levels
(251 U/l) and low EBV DNA
(1010 copies/ml) load, 6 years
after lung transplantation. FDG-
PET/CTwas requested after pal-
pable lymphadenopathy was
clinically detected. Maximum in-
tensity projection FDG-PET im-
age shows metabolically active
supraclavicular and mediastinal
lymph nodes, and a large conflu-
ent abdominal lesion. Axial fused
PET/CT (top right) and CT (bot-
tom right) show the metabolically
active supraclavicular lymph
node, which proved to be mono-
morphic PTLD after biopsy
its importance as a predictor of PTLD development [3,
27–31]. Nonetheless, EBV-DNA load does not seem to affect
the detection performance of FDG-PET/CT. One potential
explanation is the high percentage of EBV-negative PTLD
in our study population, which may have decreased the clin-
ical utility of the EBV-DNA load covariate. Yet, in a sub-
analysis of only EBV-positive PTLD patients, we could not
demonstrate a relationship between EBVDNA load and a true
positive FDG-PET/CT either. We hypothesize that a single
time cutoff value may not be indicative of imminent PTLD
and consequently the need for FDG-PET/CT scanning.
Instead, changes over time in EBVDNA load may yield more
clinically relevant information as proposed by other studies
[32, 33].
Due to the retrospective design of this study, information
on immunosuppression adjustments was not available. As a
consequence, it was not possible to evaluate EBV-DNA load
changes over time as this is affected by immunosuppression
intensity. PTLD patient population is inherently heteroge-
neous with regard to medical history, immunosuppression reg-
imens, and treatment approaches. In our retrospective study,
heterogeneity might have been introduced by the 8-year
Table 5 Description false positive/negative cases
Readers’ differential diagnosis* Location FDG uptake Final diagnosis/outcome
False positive (n = 6) PTLD
Pelvic malignancy
Recto-uterine pouch Condyloma acuminata
PTLD Round ligament, intra-abdominal,




Cervical, retroperitoneal lymph nodes, liver Spontaneous recovery
PTLD
Disseminated infection
Supraclavicular, mediastinal, hilar and




Lung Small cell carcinoma
PTLD Mediastinal lymph nodes, lung Aspergillus infection
False negative (n = 5) Inflammation
PTLD




Lung Classic non-Hodgkin PTLD lung
Physiologic uptake Tonsils, adenoids Non-destructive PTLD tonsils
Physiologic uptake Pelvis Polymorphic PTLD rectum
Unspecific lung infiltrate No uptake Monomorphic PTLD lung
*In order of most likely diagnosis
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Fig. 2 A 62-year-old male in
which elevated LDH levels
(347 U/l) and EBV-DNA load
(1,032,500 copies/ml) were found
after clinical monitoring within
1 year after kidney transplanta-
tion. FDG-PET/CTwas subse-
quently requested. Maximum in-
tensity projection FDG-PET
shows disseminated metabolical-
ly active cervical, mediastinal,
and lung parenchymal lesions
with focal pararenal, native kid-
ney, mesenteric, and liver lesions.
Axial fused FDG-PET/CT (top
right) and CT (bottom right) show
a metabolically active
supraclavicular lymph node that
proved to be a granulomatous in-
flammation due to a mycobacte-
rium after biopsy
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